Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tandem Diabetes Care ( (TNDM) ) has issued an announcement.
On November 7, 2025, Tandem Diabetes Care appointed Sandra Beaver to its Board of Directors, expanding the board from eight to nine members. Ms. Beaver, a seasoned finance executive with over 20 years of experience, will serve on the Audit Committee and the Cybersecurity and Data Privacy Committee. Her appointment is expected to support Tandem’s growth strategy as it continues to innovate in digital health solutions and expand into new markets.
The most recent analyst rating on (TNDM) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Tandem Diabetes Care stock, see the TNDM Stock Forecast page.
Spark’s Take on TNDM Stock
According to Spark, TipRanks’ AI Analyst, TNDM is a Neutral.
Tandem Diabetes Care’s overall stock score is primarily influenced by its financial challenges, including declining revenue and high leverage. However, the positive sentiment from the recent earnings call and favorable technical indicators provide some optimism. Valuation remains a concern due to negative earnings and lack of dividends.
To see Spark’s full report on TNDM stock, click here.
More about Tandem Diabetes Care
Tandem Diabetes Care is a global insulin delivery and diabetes technology company based in San Diego, California. It manufactures and sells advanced automated insulin delivery systems, including the Tandem Mobi system and the t:slim X2 insulin pump, both featuring Control-IQ+ advanced hybrid closed-loop technology.
Average Trading Volume: 1,989,644
Technical Sentiment Signal: Sell
Current Market Cap: $1.11B
For detailed information about TNDM stock, go to TipRanks’ Stock Analysis page.